Antifungal Activities of SCY-078 (MK-3118) and Standard Antifungal Agents against Clinical Non-Aspergillus Mold Isolates

被引：78
作者：
Lamoth, Frederic [1 ,2 ,3 ,4 ]
Alexander, Barbara D. [1 ,2 ]
机构：
[1] Duke Univ, Ctr Med, Div Infect Dis & Int Hlth, Dept Med, Durham, NC 27708 USA
[2] Duke Univ, Ctr Med, Clin Microbiol Lab, Dept Pathol, Durham, NC USA
[3] Univ Lausanne Hosp, Infect Dis Serv, Dept Med, Lausanne, Switzerland
[4] Univ Lausanne Hosp, Inst Microbiol, Lausanne, Switzerland
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2015年 / 59卷 / 07期
基金：
瑞士国家科学基金会;
关键词：
GLUCAN SYNTHASE INHIBITOR; INFECTIONS; SPP; HYALOHYPHOMYCOSIS; SUSCEPTIBILITY; ENFUMAFUNGIN; PERITONITIS; DISCOVERY; CLSI;
D O I：
10.1128/AAC.00234-15
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
The limited armamentarium of active and oral antifungal drugs against emerging non-Aspergillus molds is of particular concern. Current antifungal agents and the new orally available beta-1,3-D-glucan synthase inhibitor SCY-078 were tested in vitro against 135 clinical non-Aspergillus mold isolates. Akin to echinocandins, SCY-078 showed no or poor activity against Mucoromycotina and Fusarium spp. However, SCY-078 was highly active against Paecilomyces variotii and was the only compound displaying some activity against notoriously panresistant Scedosporium prolificans.
引用
收藏
页码：4308 / 4311
页数：4
相关论文
共 19 条
[1]  
[Anonymous], 2008, Reference method for broth dilution antifungal susceptibility testing of yeasts
[2]   Neglected and emerging fungal infections: review of hyalohyphomycosis by Paecilomyces lilacinus focusing in disease burden, in vitro antifungal susceptibility and management [J].
Antas, Paulo R. Z. ;
Brito, Marcelly M. S. ;
Peixoto, Erika ;
Ponte, Carlos G. G. ;
Borba, Cintia M. .
MICROBES AND INFECTION, 2012, 14 (01) :1-8
[3]   Susceptibility testing and molecular classification of Paecilomyces spp. [J].
Castelli, Maria Victoria ;
Alastruey-Izquierdo, Ana ;
Cuesta, Isabel ;
Monzon, Araceli ;
Mellado, Emilia ;
Rodriguez-Tudela, Juan L. ;
Cuenca-Estrella, Manuel .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (08) :2926-2928
[4]   Invasive Scopulariopsis brevicaulis infection in an immunocompromised patient and review of prior cases caused by Scopulariopsis and Microascus species [J].
Iwen, Peter C. ;
Schutte, Stephanie D. ;
Florescu, Diana F. ;
Noel-Hurst, Rhonda K. ;
Sigler, Lynne .
MEDICAL MYCOLOGY, 2012, 50 (06) :561-569
[5]   Enfumafungin Derivative MK-3118 Shows Increased In Vitro Potency against Clinical Echinocandin-Resistant Candida Species and Aspergillus Species Isolates [J].
Jimenez-Ortigosa, Cristina ;
Paderu, Padmaja ;
Motyl, Mary R. ;
Perlin, David S. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (02) :1248-1251
[6]   Scedosporium infection in a tertiary care cancer center:: A review of 25 cases from 1989-2006 [J].
Lamaris, Gregory A. ;
Chamilos, Georgios ;
Lewis, Russell E. ;
Safdar, Amar ;
Raad, Issam I. ;
Kontoyiannis, Dimitrios P. .
CLINICAL INFECTIOUS DISEASES, 2006, 43 (12) :1580-1584
[7]   Mucormycosis in Organ and Stem Cell Transplant Recipients [J].
Lanternier, Fanny ;
Sun, Hsin-Yun ;
Ribaud, Patricia ;
Singh, Nina ;
Kontoyiannis, Dimitrios P. ;
Lortholary, Olivier .
CLINICAL INFECTIOUS DISEASES, 2012, 54 (11) :1629-1636
[8]   Pharmacodynamic Target Evaluation of a Novel Oral Glucan Synthase Inhibitor, SCY-078 (MK-3118), Using an In Vivo Murine Invasive Candidiasis Model [J].
Lepak, Alexander J. ;
Marchillo, Karen ;
Andes, David R. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (02) :1265-1272
[9]   Fusarium Infections in Immunocompromised Patients [J].
Nucci, Marcio ;
Anaissie, Elias .
CLINICAL MICROBIOLOGY REVIEWS, 2007, 20 (04) :695-704
[10]   Discovery of novel antifungal (1,3)-β-D-glucan synthase inhibitors [J].
Onishi, J ;
Meinz, M ;
Thompson, J ;
Curotto, J ;
Dreikorn, S ;
Rosenbach, M ;
Douglas, C ;
Abruzzo, G ;
Flattery, A ;
Kong, L ;
Cabello, A ;
Vicente, F ;
Pelaez, F ;
Diez, MT ;
Martin, I ;
Bills, G ;
Giacobbe, R ;
Dombrowski, A ;
Schwartz, R ;
Morris, S ;
Harris, G ;
Tsipouras, A ;
Wilson, K ;
Kurtz, MB .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (02) :368-377
12